Roger Guillemin's first-person account of the 1972 discovery of somatostatin, the 14-residue hypothalamic peptide that inhibits growth hormone release. He recounts the isolation, sequencing, and synthesis of the molecule and how he proposed the name somatostatin over the acronym SRIF. He also notes somatostatin's later detection in pancreatic delta-cells and the GI tract, and subsequent developments including the analogs octreotide and lanreotide.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.